Co-founders Ugur Sahin and Özlem Türeci have named their new Mainz-headquartered pharmaceutical venture Arife, confirming plans to transition out of BioNTech by late 2026. The new firm will focus on developing the next generation of mRNA-based therapeutics, while both founders retain their equity stakes in the COVID-19 vaccine pioneer.
The Bottom Line
- Leadership Transition: Co-founder Ugur Sahin will step down as CEO, handing leadership of BioNTech to incoming chief executive Guido Oelkers by February 1, 2027.
- Strategic Pivot: While Sahin and Türeci launch Arife to push forward mRNA innovation, BioNTech has formally shifted its primary internal pipeline focus toward oncology and cancer therapies.
- Corporate Continuity: Although exiting operational roles by the end of 2026, both founders will maintain their financial alignment with BioNTech as long-term shareholders.
The Genesis of Arife and the Post-BioNTech Roadmap
According to corporate filings confirmed by a company spokesperson to the Handelsblatt, the new enterprise spearheaded by Ugur Sahin and Özlem Türeci officially carries the name Arife. The startup will concentrate its operations in Mainz, focusing on research, development, manufacturing, and commercialization of next-generation pharmaceutical products.
The groundwork for this departure was laid in the spring, when Sahin and Türeci publicly communicated their intention to step away from their operational posts at BioNTech by the close of 2026. Despite relinquishing executive duties, the pair intends to preserve their financial stake, remaining committed shareholders as the company enters its next corporate epoch.
Executive Succession and Strategic Realignment
To fill the leadership void left by Sahin, BioNTech has tapped seasoned pharma executive Guido Oelkers to assume the role of Chief Executive Officer. Oelkers is scheduled to officially take the helm no later than February 1 of the coming year, inheriting a corporate titan that achieved household-name status during the global health crisis.
Here is the math on that transformation: during the height of the COVID-19 pandemic, BioNTech partnered with U.S. pharmaceutical giant Pfizer to deliver the first globally authorized vaccine against COVID-19. That milestone commercial success flooded the balance sheet with billion-euro profits, providing the capital reserves that now fund advanced clinical trials.
| Metric / Milestone | Previous Era (Pandemic Peak) | Current Transition Phase (2026) |
|---|---|---|
| Chief Executive Officer | Ugur Sahin | Guido Oelkers (Effective Feb 1, 2027) |
| Core Pipeline Focus | Covid-19 Vaccines | Oncology & Next-Gen mRNA |
| Founders’ Operational Status | Active Executive Leadership | Departing by Late 2026 (Launching Arife) |
Shifting Horizons in Onset Therapeutics
While Sahin and Türeci turn their attention toward foundational mRNA innovations via Arife, BioNTech has recalibrated its clinical priorities. The Mainz-based enterprise has systematically pivoted its core research focus away from pandemic-era viral countermeasures toward the complex field of oncology.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
